Michael Van Ameringen, MD, FRCPC, is a Professor in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. His current research is focused on the psychopharmacology of Anxiety Disorders and comorbid Mood Disorders, Obsessive Compulsive and Related Disorders, ADHD, the role of the gut microbiome in psychiatry, and treatment resistance. Other research interests include medical cannabis for anxiety and related disorders, use of Psychedelics in mental health disorders, problematic internet use and the use of mobile mental health apps and technology-based treatments. He was a member of the Steering Committee for the Canadian Anxiety Disorder Treatment Guidelines, and the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders.
He is Co-Chair of the International College of Obsessive-Compulsive Spectrum Disorders; a member of the Scientific Council of the Anxiety and Depression Association of America and of Anxiety Canada; Associate Editor for the International Journal of Psychiatry in Clinical Practice and is on the editorial board for the journal Depression and Anxiety Journal of Psychiatric Research and Comprehensive Psychiatry; the Anxiety Lead for The Canadian Network for Mood and Anxiety Treatments (CANMAT); an associate faculty member of the Michael G. DeGroote Centre for Medicinal Cannabis Research; and the Director of the ADHD Fellowship Program in the Department of Psychiatry and Behavioural Neurosciences at McMaster University. Dr. Van Ameringen has published widely in the area of OCD, ADHD and Anxiety Disorders.